Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review

por Meijboom, Rosanne W., Gardarsdottir, Helga, Egberts, Toine C. G., Giezen, Thijs J.
Publicado 2021

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept

por Meijboom, Rosanne W., Gardarsdottir, Helga, Becker, Matthijs L., ten Wolde, Saskia, Egberts, Toine C. G., Giezen, Thijs J.
Publicado 2021

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar

por Meijboom, Rosanne W., Gardarsdottir, Helga, Becker, Matthijs L., Movig, Kris L. L., Kuijvenhoven, Johan, Egberts, Toine C. G., Giezen, Thijs J.
Publicado 2023

Switching TNFα inhibitors: Patterns and determinants

por Meijboom, Rosanne W., Gardarsdottir, Helga, Becker, Matthijs L., de Groot, Mark C. H., Movig, Kris L. L., Kuijvenhoven, Johan, Egberts, Toine C. G., Leufkens, Hubert G. M., Giezen, Thijs J.
Publicado 2021